Literature DB >> 10924702

Permanent and temporary inactivation of the hippocampus impairs T-maze footshock avoidance acquisition and retention.

S A Farr1, W A Banks, M E La Scola, J F Flood1, J E Morley.   

Abstract

The hippocampus is widely recognized as playing an important role in learning and memory. Lesions of the hippocampus can disrupt spatial navigational learning and memory and injection of drugs into the hippocampus can affect both spatial navigational and nonspatial tasks. In the current studies we tested the effects of bilateral of electrolytic lesions and reversible inactivation of the hippocampus on acquisition and retention of T-maze footshock avoidance conditioning. Electrolytic lesions, which destroyed 31+/-0.04% of the hippocampus, significantly impaired acquisition and retention for T-maze footshock avoidance. No differences were found in motivation to avoid shock, open field activity, or foot shock sensitivity between lesion and control groups. Temporary inactivation of the hippocampus with lidocaine administered immediately before training disrupted acquisition and retention for T-maze footshock avoidance. Temporary hippocampal inactivation performed just prior to retention testing and post-training inactivation in mice trained to first avoidance had no effect on retention. However, temporary post-training inactivation in 'undertrained' (enough trials to remember 1 week later if treated with saline, but not allowed to make the avoidance response) mice impaired retention. The current findings indicate that the hippocampus plays an important role in learning and memory processing in the aversive T-maze paradigm.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10924702     DOI: 10.1016/s0006-8993(00)02495-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  11 in total

1.  Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins.

Authors:  Naoko Nonaka; Susan A Farr; Tomoya Nakamachi; John E Morley; Masanori Nakamura; Seiji Shioda; William A Banks
Journal:  Peptides       Date:  2012-06-09       Impact factor: 3.750

2.  Chronic peripheral administration of somatostatin receptor subtype-4 agonist NNC 26-9100 enhances learning and memory in SAMP8 mice.

Authors:  Karin E Sandoval; Susan A Farr; William A Banks; Michael L Niehoff; John E Morley; Albert M Crider; Ken A Witt
Journal:  Eur J Pharmacol       Date:  2010-12-24       Impact factor: 4.432

3.  Synthesis and structure-activity relationships of 3,4,5-trisubstituted-1,2,4-triazoles: high affinity and selective somatostatin receptor-4 agonists for Alzheimer's disease treatment.

Authors:  William L Neumann; Karin E Sandoval; Shirin Mobayen; Mahsa Minaeian; Stephen G Kukielski; Khush N Srabony; Rafael Frare; Olivia Slater; Susan A Farr; Michael L Niehoff; Audrey Hospital; Maria Kontoyianni; A Michael Crider; Ken A Witt
Journal:  RSC Med Chem       Date:  2021-05-26

4.  Central and peripheral administration of antisense oligonucleotide targeting amyloid-β protein precursor improves learning and memory and reduces neuroinflammatory cytokines in Tg2576 (AβPPswe) mice.

Authors:  Susan A Farr; Michelle A Erickson; Michael L Niehoff; William A Banks; John E Morley
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

5.  A novel touchscreen-automated paired-associate learning (PAL) task sensitive to pharmacological manipulation of the hippocampus: a translational rodent model of cognitive impairments in neurodegenerative disease.

Authors:  J C Talpos; B D Winters; R Dias; L M Saksida; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2009-04-09       Impact factor: 4.530

6.  Obesity and hypertriglyceridemia produce cognitive impairment.

Authors:  Susan A Farr; Kelvin A Yamada; D Allan Butterfield; H Mohammad Abdul; Lin Xu; Nicole E Miller; William A Banks; John E Morley
Journal:  Endocrinology       Date:  2008-02-14       Impact factor: 4.736

7.  SAMP8 mice have altered hippocampal gene expression in long term potentiation, phosphatidylinositol signaling, and endocytosis pathways.

Authors:  Harvey J Armbrecht; Akbar M Siddiqui; Michael Green; Susan A Farr; Vijaya B Kumar; William A Banks; Ping Patrick; Gul N Shah; John E Morley
Journal:  Neurobiol Aging       Date:  2013-08-19       Impact factor: 4.673

8.  The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.

Authors:  Henrik H Hansen; Katrine Fabricius; Pernille Barkholt; Michael L Niehoff; John E Morley; Jacob Jelsing; Charles Pyke; Lotte Bjerre Knudsen; Susan A Farr; Niels Vrang
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

9.  Pharmacological activation of the nuclear receptor REV-ERB reverses cognitive deficits and reduces amyloid-β burden in a mouse model of Alzheimer's disease.

Authors:  Deborah A Roby; Fernanda Ruiz; Bailey A Kermath; Jaymie R Voorhees; Michael Niehoff; Jinsong Zhang; John E Morley; Erik S Musiek; Susan A Farr; Thomas P Burris
Journal:  PLoS One       Date:  2019-04-11       Impact factor: 3.240

10.  Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.

Authors:  Henrik H Hansen; Katrine Fabricius; Pernille Barkholt; Pernille Kongsbak-Wismann; Chantal Schlumberger; Jacob Jelsing; Dick Terwel; Annelies Termont; Charles Pyke; Lotte Bjerre Knudsen; Niels Vrang
Journal:  PLoS One       Date:  2016-07-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.